Remicade

E49851
biologic drug brand name drug monoclonal antibody

Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Jump to: Statements Referenced by

Statements (49)

Predicate Object
instanceOf biologic drug ⓘ
brand name drug ⓘ
monoclonal antibody ⓘ
hasActiveIngredient infliximab ⓘ
hasApprovalYear 1998 ⓘ
hasATCCode L04AB02 ⓘ
hasBiosimilar Avsola ⓘ
Inflectra ⓘ
Ixifi ⓘ
Renflexis ⓘ
hasBlackBoxWarning malignancy ⓘ
serious infections ⓘ
hasDosingRegimen induction and maintenance ⓘ
hasDrugClass tumor necrosis factor alpha inhibitor ⓘ
hasEffect reduces inflammation ⓘ
suppresses immune response ⓘ
hasGenericName infliximab ⓘ
hasHalfLife approximately 7 to 12 days ⓘ
hasInductionSchedule weeks 0 2 and 6 ⓘ
hasMaintenanceInterval every 6 to 8 weeks ⓘ
hasMechanismOfAction binds TNF alpha and neutralizes its activity ⓘ
hasMolecularType chimeric monoclonal antibody ⓘ
hasPregnancyCategory B (historical US FDA classification) ⓘ
hasRouteOfAdministration intravenous infusion ⓘ
hasSpeciesComponents human ⓘ
mouse ⓘ
hasTarget tumor necrosis factor alpha ⓘ
isAdministeredBy healthcare professional ⓘ
isAdministeredIn hospital ⓘ
infusion center ⓘ
isApprovedBy European Medicines Agency ⓘ
Food and Drug Administration ⓘ
surface form: U.S. Food and Drug Administration
isCoDevelopedBy Janssen Biotech ⓘ
Merck & Co. ⓘ
isContraindicatedIn patients with active serious infections ⓘ
severe heart failure ⓘ
isManufacturedBy Janssen Biotech ⓘ
isOftenUsedWith methotrexate ⓘ
isUsedFor Crohn’s disease ⓘ
ankylosing spondylitis ⓘ
plaque psoriasis ⓘ
psoriatic arthritis ⓘ
rheumatoid arthritis ⓘ
ulcerative colitis ⓘ
isUsedIn adult patients ⓘ
pediatric patients with certain indications ⓘ
mayCause hepatitis B reactivation ⓘ
infusion reactions ⓘ
reactivation of latent tuberculosis ⓘ

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.